肿瘤免疫治疗中免疫检查点阻断剂的研究进展

Research progress of immune checkpoint inhibitors in tumor immunotherapy

肿瘤治疗的免疫学疗法包括治疗性疫苗、细胞因子、免疫调节剂、免疫检查点阻断剂和T细胞过继传输。其中,最有希望的策略之一是免疫检查点阻断。研究证实,阻断一些检查点如CTLA-4和PD-1,对实体肿瘤的治疗具有免疫调控作用。免疫检查点靶向封闭药物代表一类突破性药物,可为实体肿瘤的治疗及癌症免疫新疗法带来更大的希望。本文就免疫检查点阻断剂在实体肿瘤治疗中的应用做一综述。

Current immunotherapy for cancer includes therapeutic vaccines,cytokines,immune modulators,immune checkpoint inhibitors,and T cell adoptive transfer.The blockade of immune checkpoints is one of the most promising strategies to activate therapeutic antitumor immunity.The blockade of one of these checkpoints,such as cytotoxic T lymphocyte antigen-4（CTLA-4） or the programmed death 1（PD-1） receptor,has recently been found to be active to achieve an immune-modulation approach in the treatment of solid tumors.The immune checkpoint blockade targeted agents might represent breakthrough drugs in the treatment of solid tumors and have generated greater expectations in the field of cancer immunotherapy.This review will focus on the checkpoint inhibitors application in the treatment of solid tumors.